Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
143
resultados
Última actualización
13/04/2026 [11:17:00]
Resultados 25 a 50 de 143
Resumen de: WO2026027669A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Resumen de: US20260036584A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: CN121454070A
本发明公开了琥珀酸对坏死性小肠结肠炎影响机制的研究方法，涉及生物医学研究技术领域；包括如下步骤：S1：动物模型建立：选择新生小鼠，随机分为4组；S2：干预周期：持续处理3‑5天，每日记录体重、存活率及存活状态；S3：样本采集：处死小鼠，取肠组织，分装用于不同检测；S4：多维度检测；S5：数据分析：整合表型、病理、分子数据，验证琥珀酸‑SUCNR1轴的功能。本发明构建了完整的研究琥珀酸‑SUCNR1轴在坏死性小肠结肠炎中作用机制的技术体系，通过动物模型构建、分子机制验证和病理评估的有机结合，形成了从现象观察到机制阐明的完整证据链，确保研究结论的可靠性。
Resumen de: CN121445742A
本发明涉及双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用。本发明在炎症性肠病模型中验证得出一种全新的作用机制：炎症条件下TRIM25会介导LSD1的泛素化降解，引起肠上皮组织代谢紊乱加剧炎症。本发明通过预测TRIM25和LSD1结合的结构信息，使用虚拟药物筛选，筛到了双氢麦角胺小分子化合物，其可很好地占据TRIM25和LSD1互作的结合位点，抑制TRIM25和LSD1的互作，从而抑制LSD1的降解；在DSS诱导的小鼠结肠炎模型中，双氢麦角胺能缓解肠上皮因代谢紊乱造成的炎症激活，很好地缓解炎症性肠病的症状。上述过程作用机制明确，效果显著，实现了双氢麦角胺在治疗炎症性肠病方面的老药新用，具有较高的临床应用价值。
Resumen de: CN121426979A
The invention belongs to the technical field of biological medicine, and particularly discloses cistanche polysaccharide as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, washing, drying and crushing fresh cistanche, and removing impurities with absolute ethyl alcohol to obtain a reactant; s2, putting the reactant obtained in the step S1 into hot water for extraction, and adding absolute ethyl alcohol for precipitation after concentration to obtain crude polysaccharide; s3, adding a chloroform-n-butyl alcohol solution for deproteinization, and removing pigments by using macroporous resin; s4, chromatographic purification is conducted through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence, polysaccharide components are collected, dialysis and freeze-drying are conducted, and the cistanche deserticola polysaccharide is obtained. The cistanche deserticola polysaccharide has a remarkable anti-inflammatory effect, can improve the richness and uniformity of intestinal flora, optimize flora balance and maintain the barrier function of the intestinal tract, and has a wide prospect in preparation of medicines for preventing or treating colitis.
Resumen de: WO2026024847A2
Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.
Resumen de: EP4684799A2
Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Resumen de: CN121410275A
The invention relates to a joint detection kit for predicting endoscopic response of inflammatory bowel disease in the technical field of medical examination, and solves the technical problem that the existing single biomarker is limited in detection sensitivity and specificity. Comprising an excrement calprotectin detection reagent and an excrement lactoferrin detection reagent, a monoclonal antibody sandwich ELISA method is adopted for calprotectin detection, and the detection range is 10-3000 mu g/g; the lactoferrin is detected by adopting a chemiluminescence immunoassay method, and the detection range is 5-500mu g/g. An endoscopic response prediction scoring model is established based on calprotectin concentration X and lactoferrin concentration Y: prediction score = alpha * ln (X + 1) + beta * ln (Y + 1) + clinical correction factor, alpha is 0.65-0.75, beta is 0.45-0.55, and the clinical correction factor integrates C-reactive protein, fecal occult blood and patient age. Compared with single detection, the sensitivity is improved to 85%-88%, and the specificity is improved to 83%-86%.
Resumen de: CN121385324A
The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.
Resumen de: CN119433017A
The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.
Resumen de: US20260022426A1
Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.
Resumen de: WO2026020057A1
This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.
Resumen de: CN121344176A
The invention discloses an application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis. The invention finds that the expression of the miR-32-5p in an ulcerative colitis model under C.aldicans pre-planting is reduced, and the colon length of a mouse and the expression of intestinal barrier related protein in an NCM460 cell can be recovered by further increasing the expression of the miR-32-5p. Based on the discovery, the miR-32-5p can be used as a miRNA marker closely related to the fungal ulcerative colitis, is applied to preparation of diagnostic products and prevention and treatment drugs for the fungal ulcerative colitis, and provides a new thought and tool for noninvasive early diagnosis and later treatment of the ulcerative colitis.
Resumen de: CN121344178A
The invention provides an irritable bowel syndrome risk marker based on genomics. The risk marker comprises the following six pathogenic genes: CADM2, PHF2, PCLO, SHISA6, LRP1B and TANK. According to the invention, not only is the effect of the latest large-scale whole genome association research (GWAS) on the aspect of analyzing the genetic cause of the irritable bowel syndrome shown, but also five new genetic risk variation, potential unreported pathogenic genes and treatment targets of the irritable bowel syndrome are found; a new insight is provided for the cause of the irritable bowel syndrome, and a potential therapeutic intervention target is highlighted. The invention also provides an application based on the risk marker of the irritable bowel syndrome and a corresponding early screening kit.
Resumen de: CN121353785A
The invention discloses an inflammatory bowel disease classification and interpretable diagnosis method and system based on deep learning, an image acquisition module acquires image frames from colonoscope videos, and an image preprocessing module rejects low-quality images with high black pixel proportion and blurred images and executes color space normalization. The qualified image is sent to a double-stage segmentation model to obtain a polyp area mask image, the mask image is used for positioning an ROI image of the polyp area, the ROI image is input into a polyp classification model constructed based on a visual Transform structure, and a hyperplasia type or adenoma type classification result is obtained. According to the method, on the premise that extra cost input is not needed, the efficiency and accuracy of polyp recognition and grading in the colonoscope image are greatly improved, manual subjective errors are reduced, and the intelligent level and clinical practicability of early intestinal cancer screening are improved.
Resumen de: CN121354908A
The invention discloses a Crohn disease postoperative bad outcome prediction method combining knowledge base construction and an experience-driven self-asking mechanism, and solves the problems of insufficient interpretability, insufficient clinical data utilization, weak generalization ability and the like of an existing prediction method. The method comprises the following steps: constructing a Crohn disease special medical knowledge base, extracting disease progress related factors from medical literatures and real medical records, and carrying out expert score weighting processing to form searchable knowledge entries; retrieving related knowledge injection context from a knowledge base based on a medical record input by a user, and generating preliminary prediction by using a large language model; structured reasoning is guided through a multi-layer prompt engine, diagnosis tasks are decomposed through the thinking chain technology, and self-check before reasoning is achieved by driving a self-asking mechanism through experience. And generating an introspection problem chain according to historical error cases, iteratively optimizing the reasoning process, and finally outputting a bad outcome prediction result and a detailed analysis report. According to the method, both traceable interpretability and prediction accuracy are considered, and reliable assistance is provided for postoperative clinical management of Crohn's disease.
Resumen de: AU2024307935A1
Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.
Resumen de: AU2024283890A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: US20260016486A1
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
Resumen de: CN121324673A
The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.
Resumen de: CN121294684A
The invention relates to a microbial composition for screening an intestinal bacteria transplantation material for treating ulcerative colitis (UC) as well as a screening method and application of the microbial composition, and belongs to the technical field of screening of intestinal bacteria transplantation materials. The invention provides a microbial composition for screening an intestinal bacteria transplantation material for treating UC. The microbial composition is prepared from the following microorganisms: Escherichia coli, anaerobe przewalskii, bacteroides shavieri, ruminococcus bromide, parabacteroides faecalis and visceral odorobacter. According to the six characteristic bacteria and the relative abundance of the six characteristic bacteria constructed by the invention, an intestinal bacteria transplantation material with relatively high content of the six bacteria can be screened out, the remission rate of UC treatment can be improved to 89.5%, and intestinal barrier healing of a patient is enhanced. When the kit is used for detecting six characteristic bacteria in the intestinal bacteria transplantation material, the specificity is high, and the sensitivity is strong; and the detection process is simple, non-invasive and low in cost.
Resumen de: US20260008842A1
The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
Resumen de: CN121272040A
The invention discloses an application of SETD2 and NSD2 in diagnosis and treatment of aging of intestinal stem cells. Specifically, the invention relates to application of the intestinal stem cell aging marker or the detection reagent thereof, the intestinal stem cell aging marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging whether intestinal stem cells are aged or not. Wherein the senescence marker combination is prepared from SETD2 and NSD2 (National Solution Development 2). Meanwhile, the invention provides a detection reagent and a kit for the intestinal stem cell marker. The detection reagent or the kit can effectively judge the aging type of the intestinal stem cells, and different effective drugs are effectively used according to different types.
Resumen de: CN121280339A
The invention discloses a Crohn disease focus automatic segmentation and activity evaluation system based on deep learning, which belongs to the field of medical artificial intelligence and comprises a data preprocessing unit, a focus automatic segmentation unit, a radiomics feature extraction unit, a feature screening and dimension reduction unit and an activity classification unit. According to the method, an nnU-Net deep learning segmentation model is combined with image omics feature extraction, multi-stage feature screening and machine learning classification technologies, so that full-process automation from CTE image preprocessing, focus automatic segmentation, feature extraction and screening to activity classification is realized. The system can efficiently and accurately segment the focus of Crohn's disease, automatically assesses the disease activity based on the screened key radiomics characteristics, significantly improves the consistency, objectivity and efficiency of diagnosis, and is suitable for clinical auxiliary diagnosis and scientific research analysis.
Nº publicación: CN121276058A 06/01/2026
Solicitante:
GUANGDONG PROVINCIAL PEOPLES HOSPITAL
\u5E7F\u4E1C\u7701\u4EBA\u6C11\u533B\u9662
Resumen de: CN121276058A
The invention provides a Crohn disease early screening marker based on plasma proteomics. The early screening marker comprises the following nine proteins: CD274, CHI 3L1, REG1B, ITGAV, PRSS8, ITGA11, GDF15, DEFA1DEFA1B and IL6. The early screening marker provided by the invention can accurately and non-invasively predict CD as long as 16 years before diagnosis, which provides an important value for early screening of CD high risk groups and formulation of intervention measures. The invention also provides application of the Crohn disease early screening marker and an early screening kit for Crohn disease prediction.
BOPI
Sede Electrónica
